{
    "Trade/Device Name(s)": [
        "Clearview\u00ae Exact PBP2a Test",
        "Clearview\u00ae Exact PBP2a",
        "Clearview\u00ae PBP2a"
    ],
    "Submitter Information": "Binax, Inc.",
    "510(k) Number": "K091766",
    "Predicate Device Reference 510(k) Number(s)": [
        "K850291",
        "K011710"
    ],
    "Regulatory Class": "Class III",
    "Product Code(s)": [
        "MYI"
    ],
    "Summary Letter Date": "February 19, 2010",
    "Summary Letter Received Date": "February 22, 2010",
    "Submission Date": "February 10, 2010",
    "Regulation Number(s)": [
        "21 CFR 866.1640"
    ],
    "Regulation Name(s)": [
        "Antimicrobial Susceptibility Test Powder"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "penicillin-binding protein 2a (PBP2a)"
    ],
    "Specimen Type(s)": [
        "Bacterial isolates"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        ""
    ],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Monoclonal antibody detection"
    ],
    "Methodologies": [
        "Qualitative immunochromatographic membrane assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Test",
        "Dipstick"
    ],
    "Document Summary": "FDA 510(k) summary for Clearview\u00ae Exact PBP2a Test, a qualitative immunochromatographic assay for detecting PBP2a in Staphylococcus aureus isolates as an aid in identifying MRSA.",
    "Indications for Use Summary": "A qualitative, in vitro immunochromatographic assay for detecting PBP2a in Staphylococcus aureus isolates, aiding in detection of methicillin-resistant Staphylococcus aureus (MRSA); not intended for diagnosis or guiding treatment.",
    "fda_folder": "Microbiology"
}